The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 163:532-534, March 2006
doi: 10.1176/appi.ajp.163.3.532
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by DeRosse, P.
* Articles by Malhotra, A. K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by DeRosse, P.
* Articles by Malhotra, A. K.
Related Collections
* Schizophrenia Spectrum Disorders
* Genetics

Brief Report

Dysbindin Genotype and Negative Symptoms in Schizophrenia

Pamela DeRosse, M.A., Birgit Funke, Ph.D., Katherine E. Burdick, Ph.D., Todd Lencz, Ph.D., Jenny M. Ekholm, M.S., John M. Kane, M.D., Raju Kucherlapati, Ph.D., and Anil K. Malhotra, M.D.

OBJECTIVE: Converging evidence has demonstrated an association between variants in the dysbindin gene (DTNBP1) and schizophrenia. Recently, a DTNBP1 risk haplotype, associated with both schizophrenia and neurocognitive dysfunction, has been identified. Because neurocognitive dysfunction is commonly accompanied by negative symptoms (avolition, alogia, and affective flattening) in schizophrenia, the authors hypothesized that the presence of the risk haplotype would be significantly associated with negative symptoms. METHOD: The authors tested for an association between a DTNBP1 risk haplotype and a lifetime history of negative symptoms in 181 Caucasian patients with schizophrenia. RESULTS: A significant association was found between the presence of the risk haplotype and negative symptoms. CONCLUSIONS: These data suggest that the effect of DTNBP1 genetic variation may be associated with negative symptoms in patients with schizophrenia.




This article has been cited by other articles:


Home page
Schizophr BullHome page
P. DeRosse, T. Lencz, K. E. Burdick, S. G. Siris, J. M. Kane, and A. K. Malhotra
The Genetics of Symptom-Based Phenotypes: Toward a Molecular Classification of Schizophrenia
Schizophr Bull, November 1, 2008; 34(6): 1047 - 1053.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
X.-W. Chen, Y.-Q. Feng, C.-J. Hao, X.-L. Guo, X. He, Z.-Y. Zhou, N. Guo, H.-P. Huang, W. Xiong, H. Zheng, et al.
DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release
J. Cell Biol., October 20, 2008; 181(5): 791 - 801.
[Abstract] [Full Text] [PDF]


Home page
JWatch PsychiatryHome page
A Dysbindin Genotype Is Associated with Negative Symptoms in Schizophrenia
Journal Watch Psychiatry, April 19, 2006; 2006(419): 5 - 5.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org